Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 3, May-June, p. 389–394

Publication type: review article

Language: English

Circulating Soluble Vascular Cell Adhesion Molecule−1 and Vascular Endothelial Growth Factor in Patients with Laryngeal Squamous Cell Cancer

Ocena stężenia rozpuszczalnych form naczyniowej cząsteczki adhezyjnej oraz naczyniowo−śródbłonkowego czynnika wzrostu w surowicy pacjentów chorych na raka płaskonabłonkowego krtani

Marcin Frączek1,, Bożena Jaźwiec2,, Marcin Masalski1,, Beata Nadolska1,, Tomasz Kręcicki1,

1 Department of Otolaryngology, Silesian Piasts University of Medicine in Wrocław, Poland

2 Department of Hematology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Background. Tumor growth and subsequent metastatic spread of cancer cells are multistep processes accompanied by changes in the expressions of many growth factors and vascular adhesion molecules.
Objectives. Investigation whether serum levels of soluble vascular cell adhesion molecule−1 (sVCAM−1) and vascular endothelial growth factor (VEGF) are related to clinicopathological variables of laryngeal squamous cell cancer (LSCC) patients.
Material and Methods. The serum concentrations of sVCAM−1 and VEGF165 were investigated in 41 patients with LSCC and in 27 controls by an enzyme−linked immunosorbent assay (ELISA).
Results. In LSCC cases the mean ± SD serum concentration of sVCAM−1 was 542.1 ± 164.9 ng/ml (range: 388–1284 ng/ml) and of VEGF 519.4 ± 335.9 pg/ml (82–1374 pg/ml). The serum levels of both sVCAM−1 and VEGF were significantly elevated in LSCCs compared with the healthy controls (p < 0.05 and p < 0.001, respectively). In the control group the mean sVCAM−1 concentration was 434.8 ± 76.3 ng/ml (314.7–648.8 ng/ml) and VEGF level 263.6 ± 166.4 pg/ml (70.5–702.9 pg/ml). There were no significant differences between the serum levels of sVCAM−1 and VEGF and clinicopathological variables of the patients with LSCC. In neither the cancer cases nor the control group was a linear correlation between sVCAM−1 and VEGF serum levels found.
Conclusion. The results suggest that the serum levels of sVCAM−1 and VEGF165 are not clinically useful biomarkers for predicting tumor progression or for identifying the metastatic potential of LSCC.

Streszczenie

Wprowadzenie Wzrost guzów nowotworowych oraz tworzenie przerzutów to wieloetapowe procesy, w których często dochodzi do nadekspresji wielu czynników wzrostu i cząstek adhezyjnych.
Cel pracy. Ocena poziomu naczyniowej cząsteczki adhezyjnej−1 (sVCAM−1) oraz naczyniowo−śródbłonkowego czynnika wzrostu (VEGF) w surowicy pacjentów chorych na raka płaskonabłonkowego krtani oraz korelacja uzyskanych wyników ze wskaźnikami klinicznymi.
Materiał i metody. Stężenie rozpuszczalnych postaci sVCAM−1 i VEGF165 oceniono w surowicy krwi obwodowej pacjentów chorych na raka płaskonabłonkowego krtani oraz 27 osobowej grupie kontrolnej za pomocą metody immunoenzymatycznej (ELISA).
Wyniki. Stężenie sVCAM−1 w surowicy pacjentów z rakiem krtani wynosiło 388–1284 ng/ml (średnia 542,1 ng/ml; SD 164,9), stężenie VEGF 82–1374 pg/ml (średnia 519,4 pg/ml; SD 335,9). Stężenia sVCAM−1 i VEGF były istotnie statystycznie większe w surowicy pacjentów chorych na nowotwór w porównaniu z grupą kontrolną (odpowiednio p < 0,05 i p < 0,001). W grupie kontrolnej stężenie sVCAM−1 wynosiło 314,7–648,8 ng/ml (średnia 434,8 ng/ml; SD 76,3), a stężenie VEGF 70,5–702,9 pg/ml (średnia 263,6 pg/ml; SD 166,4). Nie stwierdzono istotnych zależności między stężeniem sVCAM−1 i VEGF a wskaźnikami klinicznymi i patologicznymi. Zarówno w grupie pacjentów chorych na raka krtani, jak i w grupie kontrolnej nie wykazano liniowej zależności między stężeniami obu badanych markerów.
Wnioski. Uzyskane wyniki sugerują, że ocena stężenia sVCAM−1 oraz VEGF w surowicy pacjentów chorych na raka płaskonabłonkowego krtani nie ma klinicznego znaczenia w przewidywaniu progresji raka i ocenie możliwości tworzenia przerzutów.

Key words

laryngeal cancer, sVCAM−1, VEGF

Słowa kluczowe

rak krtani, sVCAM−1, VEGF

References (22)

  1. Nelson H, Ramsey PS, Donohue JH: Cell adhesion molecule expression within the microvasculature of human colorectal malignancies. Clin Immunol Immunopathol 1994, 72, 129–136.
  2. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine−induced endothelial protein that binds to lymphocytes. Cell 1989, 59, 1203–1211.
  3. Ferrara N, Davis−Smyth T: The biology of vascular endothelial growth factor. Endocrine Rev 1997, 18, 4–25.
  4. Riedel F, Götte K, Schwalb J, ·Wirtz H, BerglerW, Hörmann K: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 2000, 257, 332–336.
  5. Zhang GJ, Adachi I: Serum levels of soluble intercellular adhesion molecule−1 and E−selectin in metastatic breast carcinoma: Correlations with clinicopathological features and prognosis. Int J Oncol 1999, 14, 71–77.
  6. Alexiou D, Karayiannakis AJ, Syrigos KN: Serum levels of E−selectin, ICAM−1 and VCAM−1 in colorectal cancer patients: Correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001, 37, 2392–2397.
  7. Liu C−M, Sheen T−S, Shun C−T: Circulating intercellular adhesion molecule 1 (ICAM−1), E−selectin and vascular cell adhesion molecule 1 (VCAM−1) in head and neck cancer. Br J Cancer 1999, 79(2), 360–362.
  8. Liotta LA, Steeg PS, Stetler−Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327–336.
  9. Byrne GJ, Ghellal A, Iddon J: Serum soluble vascular cell adhesion molecule−1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000, 92, 1329–1336.
  10. Kamezaki S, Kurozawa Y, Iwai N, Hosoda T: Serum levels of soluble ICAM−1 and VCAM−1 predict pre−clinical cancer. Eur J Cancer 2005, 41, 2355–2359.
  11. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer 1997, 76, 1221–1227.
  12. Ding Y−B, Chen G−Y, Xia J−G, Zang X−W, Yang H−Y: Association of VCAM−1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2003, 9(7), 1409–1414.
  13. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM: Association of preoperative plasma levels of Vascular Endothelial Growth Factor and soluble Vascular Cell Adhesion Molecule−1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004, 22, 1655–1663.
  14. Kawano T, Yanoma S, Nakamura Y, Shiono O, Kokatu T, Kubota A: Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM−1, and VCAM−1 as tumor markers in head and neck cancer. Am J Otolaryngol 2005, 26(5), 308–313.
  15. Ohydo I, Doi T, Mendo H, Hosokawa H, Nishikawa Y, Tanimizu M: Clinical significance of plasma Vascular Endothelial Growth Factor in gastrointestinal cancer. Eur J Cancer 1998, 34(13), 2041–2045.
  16. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K: Vascular endothelial growth factor (VEGF) expression in coronary artherosclerotic lesions: possible pathophysiological significance of VEGF in progression of artherosclerosis. Circulation 1998, 98, 2108–2116.
  17. Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y: Plasma concentrations of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998, 47, 27–30.
  18. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S: Peripheral blood T−lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995, 55, 4140–4145.
  19. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol Biol Cell 1992, 3, 211–220.
  20. Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin−induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94, 663–668.
  21. Vermeulen PB, Salven P, Benay I, Gasparini G, Dirix LY: Blood platelets and serum VEGF in cancer patients. Br J Cancer Lett 1999, 79, 370–371.
  22. Harrison P, Wilbourn B, Debili N, Vainchenker W, Breton J, Gorius J: Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989, 84, 1320–1324.
© Wroclaw Medical University